VYNE Therapeutics is a technology company.
VYNE Therapeutics has raised $51.0M across 1 funding round.
VYNE Therapeutics has raised $51.0M in total across 1 funding round.
VYNE Therapeutics has raised $51.0M in total across 1 funding round.
VYNE Therapeutics's investors include venBio.
# VYNE Therapeutics: Correcting the Record
VYNE Therapeutics is not a technology company—it is a biopharmaceutical company focused on developing therapies for immuno-inflammatory conditions.[1][3]
VYNE Therapeutics is a biopharmaceutical company committed to addressing unmet needs in patients with immuno-inflammatory conditions.[3] Rather than building software or hardware products, VYNE develops proprietary, innovative medicines designed to treat difficult therapeutic challenges.[1] The company operates as an entrepreneurial biotech firm that questions traditional assumptions in drug development and seeks to reimagine solutions for conditions with high unmet medical needs.[1]
The company is publicly traded on NASDAQ under the ticker VYNE, with a stock price of $0.58 as of December 31, 2025.[3]
VYNE's approach centers on several key principles:
The search results provided do not include details about VYNE's founding history, specific product pipeline, recent clinical trial results, or detailed financial performance—information that would be essential for a comprehensive company analysis. To provide a complete overview of VYNE's origin story, market position, and future outlook, additional sources would be needed.
VYNE Therapeutics has raised $51.0M across 1 funding round. Most recently, it raised $51.0M Series C in July 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2017 | $51.0M Series C | venBio |